TGF-β Superfamily Receptors—Targets for Antiangiogenic Therapy?

The TGF-β pathway controls a broad range of cellular behavior including cell proliferation, differentiation, and apoptosis of various cell types including tumor cells, endothelial cells, immune cells, and fibroblasts. Besides TGF-β's direct effects on tumor growth and its involvement in neoangiogenesis have received recent attention. Germline mutations in TGF-β receptors or coreceptors causing Hereditary Hemorrhagic Teleangiectasia and the Loeys-Dietz syndrome underline the involvement of TGF-β in vessel formation and maturation. Several therapeutic approaches are evaluated at present targeting the TGF-β pathway including utilization of antisense oligonucleotides against TGF-β itself or antibodies or small molecule inhibitors of TGF-β receptors. Some of these therapeutic agents have already entered the clinical arena including an antibody against the endothelium specific TGF-β class I receptor ALK-1 targeting tumor vasculature. In conclusion, therapeutic manipulation of the TGF-β pathway opens great opportunities in future cancer therapy.

[1]  Carolyn Gibson,et al.  Genes and development. , 2011, European journal of oral sciences.

[2]  G. Giannelli,et al.  Down‐regulation of connective tissue growth factor by inhibition of transforming growth factor β blocks the tumor–stroma cross‐talk and tumor progression in hepatocellular carcinoma , 2010, Hepatology.

[3]  G. Giannelli,et al.  Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo‐angiogenesis regulation , 2009, Hepatology.

[4]  O. Legrand,et al.  High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. , 2009, Blood.

[5]  B. Seon,et al.  Anti‐endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature , 2009, International journal of cancer.

[6]  藤田 琢也.  Inhibition of transforming growth factor-β-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types , 2009 .

[7]  K. Boström,et al.  Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. , 2009, Blood.

[8]  U. Bogdahn,et al.  Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Bixiang Zhang,et al.  Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. , 2009, Cancer letters.

[10]  G. Giannelli,et al.  Targeting transforming growth factor (TGF)‐βRI inhibits activation of β1 integrin and blocks vascular invasion in hepatocellular carcinoma , 2009, Hepatology.

[11]  K. Chan,et al.  The prognostic significance of BMP-6 signaling in prostate cancer , 2008, Modern Pathology.

[12]  M. Konopleva,et al.  TGF‐β receptor kinase inhibitor LY2109761 reverses the anti‐apoptotic effects of TGF‐β1 in myelo‐monocytic leukaemic cells co‐cultured with stromal cells , 2008, British journal of haematology.

[13]  U. Bogdahn,et al.  Results of a phase Iib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma , 2008 .

[14]  J. Berzofsky,et al.  Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGF{beta}) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC) , 2008 .

[15]  G. Giannelli,et al.  Blocking transforming growth factor–beta up‐regulates E‐cadherin and reduces migration and invasion of hepatocellular carcinoma cells , 2008, Hepatology.

[16]  Gerard C Blobe,et al.  Role of transforming growth factor-beta superfamily signaling pathways in human disease. , 2008, Biochimica et biophysica acta.

[17]  G. Tortora,et al.  LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis , 2008, Molecular Cancer Therapeutics.

[18]  Bernhard Schmierer,et al.  TGFβ–SMAD signal transduction: molecular specificity and functional flexibility , 2007, Nature Reviews Molecular Cell Biology.

[19]  Y. Wan,et al.  Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy , 2007, Clinical Cancer Research.

[20]  T. Papadopoulos,et al.  TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study , 2007, BMC Cancer.

[21]  Alison Murphy,et al.  Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness , 2007, Molecular Pharmacology.

[22]  H. Moses,et al.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. , 2007, The Journal of clinical investigation.

[23]  Jeffrey K. Cohen,et al.  Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. , 2007, American journal of clinical pathology.

[24]  M. V. Dinther,et al.  BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis , 2007, Journal of Cell Science.

[25]  K. Mohammad,et al.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. , 2007, Cancer research.

[26]  Juswinder Singh,et al.  A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection , 2007 .

[27]  G. Blobe,et al.  The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. , 2007, Cancer research.

[28]  B. Moeller,et al.  The type III TGF-β receptor suppresses breast cancer progression , 2007 .

[29]  A. Harris,et al.  The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer , 2006, British Journal of Cancer.

[30]  J. Mantil,et al.  Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma , 2006, Cancer Gene Therapy.

[31]  H. Yamagishi,et al.  A novel immunotherapeutic modality with direct hemoperfusion targeting transforming growth factor-beta prolongs the survival of tumor-bearing rats. , 2006, Oncology Report.

[32]  N. Senzer,et al.  Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  F. Tas,et al.  Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients , 2006, Melanoma research.

[34]  M. Feith,et al.  Overexpression of TGF‐β1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis , 2006, Molecular carcinogenesis.

[35]  K. Lillehei,et al.  TGF-β2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors , 2006, Journal of Neuro-Oncology.

[36]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[37]  M. Reiss,et al.  Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo , 2006, Clinical Cancer Research.

[38]  Ximing J. Yang,et al.  Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle , 2006, Molecular Cancer Therapeutics.

[39]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[40]  F. Blanco,et al.  Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. , 2006, Clinical medicine & research.

[41]  W. Greco,et al.  Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin , 2006, Cancer Immunology, Immunotherapy.

[42]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[43]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[44]  L. Aaltonen,et al.  Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. , 2005, JAMA.

[45]  S. Hayward,et al.  Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks , 2005, Oncogene.

[46]  Seong-Jin Kim,et al.  Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1 , 2004, Cancer Research.

[47]  H T Lynch,et al.  The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations , 2004, Journal of Medical Genetics.

[48]  D. Bigner,et al.  SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. , 2004, Molecular cancer therapeutics.

[49]  M. Kattan,et al.  Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression , 2004, Clinical Cancer Research.

[50]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[51]  Mark P. de Caestecker,et al.  The transforming growth factor-beta superfamily of receptors. , 2004, Cytokine & growth factor reviews.

[52]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.

[53]  Seung-Yong Jeong,et al.  Microsatellite Instability and Mutations in DNA Mismatch Repair Genes in Sporadic Colorectal Cancers , 2003, Diseases of the colon and rectum.

[54]  M. Maio,et al.  Differential levels of soluble endoglin (CD105) in myeloid malignancies , 2003, Journal of cellular physiology.

[55]  Hiroyuki Aburatani,et al.  Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor‐β in human umbilical vein endothelial cells , 2002, Journal of cellular physiology.

[56]  K. Miyazono,et al.  Smurf1 Regulates the Inhibitory Activity of Smad7 by Targeting Smad7 to the Plasma Membrane* 210 , 2002, The Journal of Biological Chemistry.

[57]  L. Wakefield,et al.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.

[58]  S. Iturria,et al.  Differential Gene Expression of TGF-β Family Members and Osteopontin in Breast Tumor Tissue: Analysis by Real-Time Quantitative PCR , 2002, Breast Cancer Research and Treatment.

[59]  P. Stattin,et al.  Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer , 2002, The Prostate.

[60]  M. Goumans,et al.  Balancing the activation state of the endothelium via two distinct TGF‐β type I receptors , 2002, The EMBO journal.

[61]  M W Kattan,et al.  Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma , 2001, Cancer.

[62]  B. Seon,et al.  Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. , 2001, Cancer research.

[63]  E. Staren.  Serum Levels of Transforming Growth Factor β1 in Patients With Breast Cancer—Invited Critique , 2001 .

[64]  R. Hennekam,et al.  Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes , 2001, The Lancet.

[65]  M. Goumans,et al.  Abnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice , 2001, The EMBO journal.

[66]  Shigeru Chiba,et al.  Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis , 2001, Oncogene.

[67]  J. Massagué,et al.  How cells read TGF-β signals , 2000, Nature Reviews Molecular Cell Biology.

[68]  J. Wrana,et al.  Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. , 2000, Molecular cell.

[69]  S. Tsujitani,et al.  An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. , 2000, Anticancer research.

[70]  Dean Y. Li,et al.  Arteriovenous malformations in mice lacking activin receptor-like kinase-1 , 2000, Nature Genetics.

[71]  M. McAsey,et al.  Endoglin Expression as a Measure of Microvessel Density in Cervical Cancer , 2000, Obstetrics and gynecology.

[72]  M. Goumans,et al.  Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. , 2000, The International journal of developmental biology.

[73]  J. G. Park,et al.  Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[75]  H. Lodish,et al.  A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. , 1999, Blood.

[76]  K. Crosier,et al.  The TGF-β type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression , 1999, Leukemia.

[77]  M. Barcos,et al.  Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  K. Shim,et al.  Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. , 1999, Cancer.

[79]  R. Derynck,et al.  Transcriptional Activators of TGF-β Responses: Smads , 1998, Cell.

[80]  R. Derynck,et al.  The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. , 1998, Genes & development.

[81]  J. Massagué,et al.  Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. , 1998, Genes & development.

[82]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[83]  J. Massagué,et al.  Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. , 1997, Genes & development.

[84]  C. Wernstedt,et al.  Phosphorylation of Ser465 and Ser467 in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor-β Signaling* , 1997, The Journal of Biological Chemistry.

[85]  Jeffrey L. Wrana,et al.  TβRI Phosphorylation of Smad2 on Ser465 and Ser467 Is Required for Smad2-Smad4 Complex Formation and Signaling* , 1997, The Journal of Biological Chemistry.

[86]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[87]  K. Miyazono,et al.  Smad6 inhibits signalling by the TGF-β superfamily , 1997, Nature.

[88]  M. Barcos,et al.  Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[90]  M. Washington,et al.  Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. , 1996, Lung cancer.

[91]  J. Massagué,et al.  Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways , 1996, Nature.

[92]  H. Lodish,et al.  A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma , 1996, Molecular and cellular biology.

[93]  D. W. Johnson,et al.  Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.

[94]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[95]  M. Anscher,et al.  Elevated Plasma Transforming Growth Factor-β1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor , 1995, Annals of surgery.

[96]  Jeffrey L. Wrana,et al.  Mechanism of activation of the TGF-β receptor , 1994, Nature.

[97]  J. Massagué,et al.  TGF-beta receptors and actions. , 1994, Biochimica et biophysica acta.

[98]  J. Grootegoed,et al.  Welcome to the family: the anti-müllerian hormone receptor , 1994, Molecular and Cellular Endocrinology.

[99]  K. Miyazono,et al.  Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein , 1994, The Journal of cell biology.

[100]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[101]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[102]  A. Anagnostou,et al.  Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[103]  J. Massagué,et al.  Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta , 1989, The Journal of cell biology.

[104]  S. Jonjić,et al.  Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes , 1989, The Journal of experimental medicine.

[105]  A. Mantovani,et al.  Granulocyte- and granulocyte– macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate , 1989, Nature.

[106]  M. Letarte,et al.  Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. , 1988, Journal of immunology.

[107]  A. Roberts,et al.  Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. , 1988, Journal of immunology.

[108]  A. Ammann,et al.  Suppression of immune cell function in vitro by recombinant human transforming growth factor-beta. , 1988, Cellular immunology.

[109]  H. Yasumitsu,et al.  High level of beta-type transforming growth factor activity in human urine obtained from cancer patients. , 1986, Japanese journal of cancer research : Gann.

[110]  M. Sporn,et al.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth , 1986, The Journal of experimental medicine.

[111]  H. Hurwitz,et al.  Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  Xiao-Fan Wang,et al.  Signaling cross-talk between TGF-β/BMP and other pathways , 2009, Cell Research.

[113]  M. Bitzer,et al.  Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS. Commentary , 2008 .

[114]  A. Bosserhoff,et al.  Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. , 2007, Cancer biomarkers : section A of Disease markers.

[115]  Z. Gatalica,et al.  Pathology of the hereditary colorectal carcinoma , 2007, Familial Cancer.

[116]  山本 芳樹.  A novel immunotherapeutic modality with direct hemoperfusion targeting transforming growth factor-β prolongs the survival of tumor-bearing rats , 2007 .

[117]  A. Bosserhoff,et al.  Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma1 , 2007 .

[118]  F. Blanco,et al.  Hereditary Hemorrhagic Telangiectasia , a Vascular Dysplasia Affecting the TGF-β Signaling Pathway , 2006 .

[119]  D. Logan,et al.  Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental angiogenesis. , 2005, Genomics.

[120]  K. Miyazono,et al.  Latent Transforming Growth Factor-/ l Associates to Fibroblast Extracellular Matrix via Latent ' II 3 FB Binding Protein , 2002 .

[121]  D. Marchuk,et al.  Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. , 2000, Developmental biology.

[122]  M. Goumans,et al.  EGF , epithelium and Gene ablation and TGF β superfamily function in mice 253 Functional analysis of the TGF β receptor / Smad pathway through gene ablation in mice , 2000 .

[123]  J. Massagué.  How cells read TGF-beta signals. , 2000, Nature reviews. Molecular cell biology.

[124]  D Falb,et al.  The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. , 1997, Cell.

[125]  D. Kingsley,et al.  The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. , 1994, Genes & development.